Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies

Thomas Van Blarcom*, Kevin Lindquist , Zea Melton, Wai Ling Cheung, Chris Wagstrom, Dan McDonough, Cendy Valle Oseguera, Sheng Ding, Andrea Rossi, Shobha Potluri, Purnima Sundar, Steven Pitts, Marina Sirota, Meri Galindo Casas, Yu Yan, Jeffrey Jones, Zygy Roe-Zurz, Surabhi Srivatsa Srinivasan, Wenwu Zhai, Jaume Pons, Arvind Rajpal, and Javier Chaparro-Riggers

Oncology Research and Development, Pfizer Inc., South San Francisco, CA, USA

ABSTRACT
The commercial success of bispecific antibodies generally has been hindered by the complexities associated with generating appropriate molecules for both research scale and large scale manufacturing purposes. Bispecific IgG (BsIgG) based on two antibodies that use an identical common light chain can be combined with a minimal set of Fc mutations to drive heavy chain heterodimerization in order to address these challenges. However, the facile generation of common light chain antibodies with properties similar to traditional monoclonal antibodies has not been demonstrated and they have only been used sparingly. Here, we describe the design of a synthetic human antibody library based on common light chains to generate antibodies with biochemical and biophysical properties that are indistinguishable to traditional therapeutic monoclonal antibodies. We used this library to generate diverse panels of well-behaved, high affinity antibodies toward a variety of epitopes across multiple antigens, including mouse 4-1BB, a therapeutically important T cell costimulatory receptor. Over 200 BsIgG toward 4-1BB were generated using an automated purification method we developed that enables milligram-scale production of BsIgG. This approach allowed us to identify antibodies with a wide range of agonistic activity that are being used to further investigate the therapeutic potential of antibodies targeting one or more epitopes of 4-1BB.

Introduction
The ability of bispecific antibodies to bind two different antigens or epitopes enables a wide range of clinical applications that cannot be addressed through traditional monoclonal monoclonal antibodies. These applications include redirecting effector cells to engage tumor cells, circumventing escape mechanisms, targeting heterogeneous tumors, actively crossing the blood-brain barrier, and enhancing tissue specificity. Even though they were first described in the literature over 50 ago, many bispecific antibodies that have entered the clinic, and the only two (catumaxomab, blinatumomab) that have been approved for therapy in the US or Europe, redirect T cells to engage tumor cells. Discovering antibodies for this therapeutic mechanism of action has generally been performed by pairing a given CD3-specific antibody with panels of tumor-associated-antigen-specific antibodies. The resulting bispecific antibodies are then screened in T cell-mediated tumor killing assays to select those that cause efficient synapse formation, which is dependent on the proximity of the epitope to the membrane. However, antibodies that modulate receptor signaling are susceptible to geometric constraints in an unpredictable manner, so their properties can only be identified empirically through antibody generation and functional screening. Therefore, it may be naive to assume this sequential approach to bispecific antibody discovery, as used for T-cell redirecting antibodies, will be successful for other mechanisms of action or result in a drug with the most optimal properties.

In order to discover bispecific antibodies with superior therapeutic properties, a greater degree of antibody generation and screening may be required compared to traditional monoclonal antibody discovery because of additional degrees of freedom. This process has been hindered by the complexities associated with generating appropriate molecules for both discovery and manufacturing purposes. Although over 60 different bispecific antibody formats that use various approaches to circumvent production issues have been described in the literature, many of these formats do not have the same level of “developability”, a term used to describe the ability to successfully manufacture a well-behaved drug. The bispecific IgG (BsIgG) format that most closely resembles monoclonal antibodies is considered by many to be the preferred choice,

CONTACT Thomas Van Blarcom thomas.vanblarcom@pfizer.com; Javier Chaparro-Riggers javier.chaparro-riegers@pfizer.com

© 2018 Thomas Van Blarcom, Kevin Lindquist, Zea Melton, Wai Ling Cheung, Chris Wagstrom, Dan McDonough, Cendy Valle Oseguera, Sheng Ding, Andrea Rossi, Shobha Potluri, Purnima Sundar, Steven Pitts, Marina Sirota, Meri Galindo Casas, Yu Yan, Jeffrey Jones, Zygy Roe-Zurz, Surabhi Srivatsa Srinivasan, Wenwu Zhai, Jaume Pons, Arvind Rajpal, and Javier Chaparro-Riggers. Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
since these are more likely to maintain the desirable properties associated with monoclonal antibodies without the need for individual customization for each antibody pair selected.7

BsIgG are challenging to produce in a single host cell because the random pairing of the two heavy and two light chains results in the expression of 10 different IgG species with only one being the BsIgG of interest. This reduces the overall yields of the BsIgG, and its relatively low concentration amongst the byproducts results in the need for elaborate purification techniques that still result in some amount of contamination with other IgG species, which poses potential clinical and regulatory risks. While alternative strategies exist to overcome this issue, they can be resource intensive14,16 or do not completely eliminate mispairing while introducing a significant mutational load, which may lead to immunogenicity.5,17,20,21

An alternative approach for single cell manufacturing of BsIgG is to use antibodies that are based on the same light chain in combination with a minimal set of Fc mutations to drive heavy chain heterodimerization.22 The resulting BsIgG can readily be purified from the two undesired byproducts.16,23 While this “common light chain” approach was introduced two decades ago,22,24 and has more recently been explored due to the renewed interest in bispecific antibodies,12,22–28 it has yet to be shown to be a reliable approach for the generation of diverse, high-affinity panels of antibodies to a variety of antigens. For example, pioneering work in this field illustrated that it was possible to generate antibodies toward multiple antigens using a library with a restricted light chain repertoire,25 but a decade later the highest affinity common light chain antibody reported without individual optimization is only 35 nM.26 More recent work described common light chain antibodies with low nanomolar and even picomolar affinities, but this was limited to just two antibodies to each of two antigens.25 Nevertheless, we expected the generation of diverse panels of high-affinity antibodies targeting a broad array of antigens would be feasible by applying the appropriate library design and synthesis techniques, since cartilaginous fish and camels naturally generate diverse panels of high affinity single variable domain antibodies.29 Further, a recent report demonstrating the ability to generate large panels of high affinity antibodies based on common heavy chain antibodies further enforced this potential.18 Manufacturing of BsIgG, however, typically requires a custom purification protocol for each BsIgG,16,23 which makes the generation of smaller quantities of non-redundant bispecific antibodies required for biophysical characterization and functional screening time consuming and labor intensive. The development of methods to expedite this process is long overdue.

We describe here a synthetic human antibody library based on a set of common light chains that was used to generate diverse panels of high affinity antibodies toward multiple antigens. To facilitate screening of BsIgG based on various combinations of antibodies, we developed a methodology including automated purification that enables the milligram-scale production of dozens of high-purity BsIgG per week. This method was utilized to generate hundreds of antibodies toward mouse 4-1BB, which were tested for agonistic activity in vitro. This approach allowed us to identify antibodies with a wide range of agonistic activity that are being used to further investigate the therapeutic potential of antibodies targeting 4-1BB.

Results

Library design

A total of four heavy chain and three light chain human germ-line frameworks were selected as the backbone for the synthetic library. VH1-69, VH3-2-3, VH5-51, VK1-39, VK3-20 and VK1-47 were chosen based on their frequency in the memory compartment of the immune repertoire obtained from 10 healthy donors, natural pairing frequencies,30–32 canonical complementarity-determining region (CDR) structural diversity34,35 and stability.36,37 These criteria were chosen to allow the generation of antibodies targeting a broad array of antigens with desirable biophysical properties while minimizing the risk of immunogenicity. The undiversified common light chain sequences were based on germline V and J segments lacking functional diversity. This resulted in CDR-L3 lengths of 9 for VK1-39 and VK3-20 and 11 for VH1-47, which, not surprisingly, also correlate with the most frequently found lengths in nature for each germline (Fig. S1A). The resulting light chain sequences for all three germlines were found in 10 donors, suggesting a low probability of immunogenicity.

The diversity introduced into the heavy chain was designed to further support the above-mentioned design criteria. Positions to diversify were limited to the CDRs and selected based on structural proximity to the antigen and abundance of natural amino acid variability.36,37 This was accomplished by analyzing representative crystal structures for each heavy chain germline found in the Protein Databank Bank (PDB) in conjunction with the immune repertoire data from over 228 donors. This analysis resulted in the generation of germline-specific designs for CDR-H1 and CDR-H2 (Fig. 1A). The amino acid diversity to include was based on the natural amino acid distribution of non-redundant naïve B cell sequences from the immune repertoire of these donors to avoid biasing the results based on clonal expansion.37 For each position selected for diversification, all amino acids found at a frequency above 1% were included with the exception of cysteine, which was excluded to avoid potential protein expression issues. The germline amino acid was used for all other positions.

For CDR-H3, the design consisted of a cassette that spanned lengths of 6 to 17 amino acids (Kabat positions 95–102), which accounted for 81% of the unique sequences found in the immune repertoire analyzed (Fig. S1B). The same cassette was used for each germline, since for a particular CDR-H3 length, there is a high degree of amino acid usage similarity across germlines (Pearson’s r = 0.93± 0.01 across lengths of 6–17 amino acids, Fig. S1D). Synthetic libraries typically use a CDR-H3 length distribution profile that mimics the bell-shaped distribution found in nature30,37 (Fig. S2A). However, combining this approach with the natural amino acid distribution found at each position results in upwards of 100,000 copies for the shorter CDR-H3 sequences, which decrease the overall library size, while longer CDR-H3 lengths containing the most diversity are under-sampled (Fig. S2B).37 To increase the number of unique CDR-H3s present in the library, this redundancy and under-sampling was minimized by using a sigmoidal-shaped length distribution profile (Fig. S2A), and the amino acid frequency profiles were smoothed by applying a damping coefficient to decrease the frequency of the more frequent clones.
while maintaining the hierarchical amino acid usage in each position (Fig. S2C). This reduced the redundancy of CDR-H3 sequences by up to 372-fold (Fig. S2B) and increased the overall diversity of the library.

**Library synthesis**

The library was constructed using the Slonomics® gene synthesis technology, which relies on a set of universal building blocks called anchors. In total, there are 4096 unique anchors that encode all combinations of DNA codons in adjacent positions \((64^2 = 4096)\). Pools of anchor molecules are assembled in a series of ligation and digestion reactions to synthesize small stretches of DNA one codon at a time, which are then combined to generate longer stretches of DNA. Anchors used in library synthesis were selected using an algorithm designed to incorporate the desired amino acids at the desired frequencies while minimizing the presence of restriction sites that are used in Slonomics®-based DNA synthesis and engineered into the frameworks of each germline for cloning. The library design also takes into consideration codon usage to maximize protein expression in the desired hosts, in this case *E. coli* and mammalian expression systems.

Library synthesis accuracy was improved by determining the incorporation efficiency of each anchor through the synthesis of 128 libraries each containing 32 different anchors at equal molar ratios to account for the 4096 unique anchors. These libraries were subjected to Roche 454 sequencing and the relative incorporations of each anchor were used to generate correction factors to compensate for their incorporation efficiency (Fig. S3A). These correction factors were used to adjust the frequency of each anchor within each pool of anchors used to assemble the library and increased the accuracy of amino acid incorporation at each position \((X^2 = 35.9 \text{ vs } 41.0, \text{ Fig. S3B})\). The positional amino acid accuracy increase was compounded when looking at the combinatorial amino acid frequency across all positions \((X^2 = 5.0 \text{ vs } 13.8, \text{ Fig. S3C})\), which is a more critical assessment of library synthesis accuracy since this is where the library diversity grows exponentially.

All combinatorial library designs result in the presence of common troublesome post-translational modifications including deamidation (NS, NG NH), isomerization (DS, DG) and protease cleavage (DP). The frequencies of these motifs vary across the different germline libraries and emerge with higher frequencies when they are present in the germline CDR sequences. For example, VH5-51 CDR-H2 has a DS motif in its germline sequence and the library design would result in this motif appearing in 88% of the CDR-H2 sequences, while VH1-69 does not have any of these motifs in its germline CDR sequences and the library design would result in each of these motifs appearing in less than 8% of the CDR-H1 and CDR-H2 sequences combined (Fig. S4). To address this issue, anchor molecules encoding these post-translational modifications were removed prior to the synthesis of CDR-H1 and CDR-H2 for each germline. This strategy significantly reduced the overall frequency of antibodies containing these motifs, while minimizing the loss of antibodies that may require these motifs in CDR-H3 for antigen specificity (Fig. 1B and 1C).

The heavy chain CDRs were assembled with undiversified framework regions that were codon optimized for both *E. coli* and mammalian expression to maximize phage display levels for antibody isolation and future expression as full-length
IgGs for functional testing, respectively. Roche 454 sequencing was used to assess the quality of the libraries prior to transformation into *E. coli*. In general, the amino acid frequencies following library synthesis correlated very well with the design, amino acid liabilities were reduced, and the desired amino acid diversity was generated (data not shown). The libraries were individually cloned based on germline and CDR-H3 length into a phagemid containing each of the three common light chains codon optimized for expression in *E. coli*. A total of 106 transformations were used for each heavy chain and light chain pairing, resulting in a total library of $9 \times 10^{11}$ transformants (Table S1).

**Antibody generation**

The libraries were used to generate antibodies toward a panel of antigens, including human EGFR, mouse 4-1BB and mouse ROR2 (Table 1). This was accomplished by subjecting the phage displayed libraries to 4 rounds of panning using antigen that was site-specifically biotinylated through an Avi-tag at the C-terminus in order to minimize potential disruption of epitopes through random conjugation or alteration of protein folding following adsorption onto 96-well plates. The biotinylated antigen was captured on streptavidin or neutravidin-coated 96-well plates to enrich for antigen-specific antibodies. A 5th and final round of panning was performed in solution with antigen concentrations as low as 5 nM to preferentially enrich for higher affinity clones.

Following the final round of panning, up to 3072 clones were randomly chosen for each antigen panned (Table 1). Each clone was sequenced and its binding to four antigens was performed using an automated phage ELISA (Fig. 2A). The diversity of each unique antibody was determined using a surface plasmon resonance (SPR) biosensor assay. Nearly 90% of clones (232 of 258) were successfully assayed and their affinity of binding was measured. Phage competition ELISA was used to select antibodies with high affinity for each antigen for further characterization. (Table 1)

**Antibody characterization**

Antigen-specific antibodies were identified from all heavy and light chain combinations, as well as all CDR-H3 lengths included in the library (Fig. 2B and Fig. 2C). The cumulative length distribution profile from antibodies toward all three antigens significantly correlated with the library design ($R^2 = 0.76$, Pearson’s one-sided $p < 0.0001$), resulting in an average length of 13.5 compared to 12.8 in the natural repertoire (Fig. 2B). While the individual and combinatorial usage of each heavy and light chain germline was highly variable across the different panning antigens, $V_{\text{H}1}$-1-69 and $V_{\text{L}1}$-47 were the most used heavy and light chains across all pannings (55% and 48%, respectively) and their pairing consistently provided the most hits (28% overall).

All unique antibodies with the desired binding specificity were selected and subjected to a phage competition ELISA to assess their relative affinities based on percent inhibition (Table 1). In order to increase assay throughput, phage competition ELISA was not normalized for phage concentrations and only one antigen concentration was used. The results between technical replicates are highly correlated (Pearson’s one-sided $p < 0.0005$) and the estimated affinities reasonably predict the actual affinities (Pearson’s one-sided $p < 0.0005$, Fig. S6). Up to 93 clones with the highest relative affinities and diverse sequences (Fig. S7) were expressed as full-length IgGs in mammalian cells and their affinities more accurately determined using a surface plasmon resonance (SPR) biosensor assay. Nearly 90% of clones (232 of 258) were successfully expressed and able to bind their respective antigens (Table 1).

**Table 1. Library panning and antibody screening summary.**

| Antigen | Library | Total | Unique (% total)* | ELISA breakdown of unique clones |
|---------|---------|-------|-------------------|---------------------------------|
| 4-1BB   | CLC     | 1536  | 887 (58%)         | [Antigen specific (%)]          |
| EGFR    | CLC     | 1344  | 601 (45%)         | [Tag specific (%)$^b$]          |
| ROR2    | CLC     | 3072  | 1244 (40%)        | [Polyreactive (%)$^d$]         |
| 4-1BB   | Shuffled| 1536  | 1224 (80%)        | [Non-binders (%)$^e$]          |

| Biacore binders (% tested) |
|-----------------------------|

| 73 (78%) |
| 73 (97%) |
| 86 (96%) |
| 84 (92%) |

| Cutoff: Deamonaded 3 standard deviations above the mean of the binding response toward insulin (outliers were removed with the standard box plot rule prior to calculating the mean and standard deviation) |

$^a$Based on heavy chain sequence only

$^b$Binds panning antigen (&gt; cutoff) but not tag control, insulin or ssDNA (. cutoff)

$^c$Binds panning antigen and tag control (&gt; cutoff) but not insulin or ssDNA (. cutoff)

$^d$Binds panning antigen (&gt; cutoff) and insulin and/or or ssDNA (. cutoff)

$^e$Do not bind panning antigen (. cutoff)
These affinities are nearly indistinguishable from antibodies generated toward the same antigens from a library containing the same heavy chain diversity, but also containing light chain diversity (Fig. S8).

A subset of 32 antibodies targeting each of these antigens based on a variety of heavy and light chain pairings was selected for epitope binning to assess their relative epitopic diversity (Fig. 2E, Fig. S9). A total of 12–22 bins and 182–269 sandwiching pairs of antibodies were identified for each antigen (Table S2). This is similar to results seen for antibodies based on diversified light chains, suggesting the use of undiversified light chains has a minimal effect on antigen epitope coverage,
which is likely attributed to CDRH3 playing a dominant role in antigen binding.\textsuperscript{46} To take advantage of single cell manufacturing of BsIgG using common light chain antibodies, the antibodies need to be derived from the same common light chain. Reanalyzing the epitope binning results based on their individual light chains reduces the epitope bins and sandwiching pairs per light chain to 1–9 and 0–70, respectively. However, the maximum number of bins and sandwiching pairs is dependent upon the number of unique antibodies tested. When this is taken into consideration, the fraction of possible bins identified is only reduced from 0.53 to 0.44 and the fraction of possible sandwiching pairs actually increases from 0.45 to 0.46.

A representative antibody for each of the three light chains was randomly selected for basic biophysical characterization to ensure they behaved similarly to other monoclonal antibodies. The molecular weights and the amount of higher molecular weight species (HMWS) were determined using size-exclusion chromatography with multi-angle light scattering (SEC-MALS). All antibodies were determined to have an expected molecular weight of approximately 150 kDa and contained less than 0.6–1.2% HMWS (Fig. S10A). Their stability was assessed by differential scanning calorimetry (DSC) to determine the melting temperature ($T_m$). The $T_m$ of the first transition ranged from 69–71°C for each of the antibodies, which are similar to other antibodies.\textsuperscript{16}

**Higher affinity antibody generation**

While the number of common light chain antibodies generated with low to sub-nanomolar affinities is substantially greater than previously reported, we were interested in determining if even higher affinity antibodies could be readily generated. Affinity optimization of individual antibodies is a routine, but time consuming practice. Alternative methods of affinity maturation have been employed to address this bottleneck, such as simultaneous affinity maturation of antibody pools.\textsuperscript{47,48} A common approach, referred to as light chain shuffling, involves taking the heavy chain of one or more antibodies and combining them with a library of light chains with the goal of identifying a more optimal pairing.\textsuperscript{47,49,50} This approach is obviously not feasible with common light chain antibodies since the goal is to maintain an identical light chain with multiple antibodies. However, the common light chain library design limits the majority of CDR-H3 sequences to pair with a single CDR-H1 and CDR-H2 combination. To identify a more optimal pairing, the CDR-H3 sequences obtained following the 4th round of panning against 4-1BB were recombined with the original library of CDR-H1 and CDR-H2\textsuperscript{48} in a process called H3-shuffling. Germline-specific primers were used to recover the CDR-H3 sequences while maintaining the $V_{\text{H}}$ and $V_{\text{L}}$ germline pairings of each clone. Library generation was readily accomplished due to the modular nature of the original library design, which incorporated unique germline-specific restriction sites in framework 3 of the heavy chains and a generic restriction site in framework 4 of the heavy chain while minimizing their occurrences in the diversified CDRs (Fig. 3A). This maintains the CDR-H3 and $V_{\text{H}}$ germline pairing and prevents the introduction of non-human sequences in framework 3, which could arise through a PCR-based assembly. Instead of returning to the polyvalent scFv phagemid used to maximize the chance of antibody recovery from the original library, a primarily monovalent Fab display phagemid was used to increase the probability of identifying high affinity clones.\textsuperscript{51} The resulting shuffled library contained $3 \times 10^{10}$ transformants and was subjected to 1 round of plate panning, then 3 rounds of solution panning as described above.

Following the 4th and final round of panning, 1536 clones were sequenced and their binding toward 4-1BB, a tag control, insulin, and ssDNA were determined using the same automated phage ELISA described above. The total number of unique antigen-specific antibodies based on the $V_{\text{H}}$ sequence increased from 750 (49% total) for the original library to 1180 (77% total) for the shuffled library (Table 1). However, only a small fraction of these shuffled library antibodies (135, 11%) had unique CDR-H3 sequences, while the majority (748, 99.7%) from the original library were unique. This was expected since the original library was designed to minimize CDR-H3 sequence redundancy while the shuffled library was designed to promote this redundancy in a search for more optimal pairings with CDR-H1 and CDR-H2. For example, 309 antibodies were identified from the shuffled library that used the same CDR-H3 sequence, but differed in CDR-H1 and CDR-H2. The heavy and light chain germline usage of these antibodies was also rather different pre- and post-shuffling (Fig. 3B).

A diverse set of 760 antigen-specific antibodies including at least one antibody from each unique CDR-H3 were subjected to a phage competition ELISA. Significantly more antibodies (94%) had percent inhibitions >50% from the shuffled library compared to the original library (6%, Fig. S11A). Antibodies sharing the same CDR-H3 sequence but differing in their CDR-H1 and CDR-H2 sequences can exhibit a nearly two order of magnitude range in relative affinities as estimated using their percent inhibitions (Fig. S11B). A set of 91 antibodies with diverse CDR-H3 sequences and higher percent inhibitions were expressed as full-length IgGs in mammalian cells and their affinities more accurately determined using an SPR biosensor assay (Fig. S11C). Nearly all the antibodies (96%) were successfully expressed and able to bind 4-1BB (Table 1). Their affinities ranged from 0.2 nM to 117 nM with an average affinity of 13 nM compared to a range of 1 nM to 1 $\mu$M and an average affinity of 128 nM for the antibodies from the original library (Fig. 3C).

A total of 16 unique epitope bins were identified across a panel of 32 antibodies including 292 sandwiching pairs (Table S2, Fig. S12). Based on individual light chains, these numbers were again reduced to 2–8 epitope bins and 11–23 sandwiching partners, but the fraction of possible bins and sandwiching pairs was only reduced from 0.50 to 0.44 and from 0.59 to 0.42, respectively. Surprisingly, the number of epitope bins and sandwiching pairs identified from the shuffled library was actually higher than from the anti-4-1BB antibodies obtained from the original library. This indicates that the shuffling process provides a straightforward method to significantly increase antibody affinity without negatively affecting the epitopic diversity.

**Bispecific antibody generation**

Identifying the two antibodies that result in a BsIgG with optimal function requires empirically testing numerous antibody
combinations. While large quantities of highly pure individual BsIgG can readily be obtained by combining Protein A and ion exchange chromatography (IEC),\textsuperscript{14-16,23} many BsIgG require the development of custom purification conditions because the isoelectric points (pI) of the two antibodies are too similar, leading to poor separation by IEC. This hinders the generation of large, diverse panels of high purity BsIgG for further testing and characterization. To circumvent this problem, we developed universal purification conditions that can be used for all antibodies regardless of their isoelectric points. Specifically, we modified our existing BsIgG technology\textsuperscript{16} by incorporating a polyhistidine tag on the C-terminus of the heavy chain with a higher pI (hIgG2 RRRR) to accentuate the pI difference from the heavy chain with a lower pI (hIgG2 EEE). Figure 4A.

Two model antibodies that utilize the same common light chain, but bind to different antigens were cloned into either the hIgG2 RRRR construct with up to a 10x polyhistidine tag or the hIgG2 EEE construct, then expressed individually or co-expressed in mammalian cells. The clarified cell culture supernatants were purified via fast protein liquid chromatography (FPLC) using Protein A and IEC. The IEC fractions expected to be the BsIgG were collected and dialyzed in phosphate-buffered saline, then confirmed to be the BsIgG by antigen binding using bio-layer interferometry (BLI). As expected, the separation of the BsIgG from the monospecific contaminants increased proportionally to the length of the polyhistidine tag, leading to robust separation of the BsIgG from the monospecific contaminants (Fig. 4B). While the 10x polyhistidine tag resulted in the most robust separation, the inclusion of the polyhistidine tag raised concerns that it may increase non-specific binding. This concern was addressed by incubating each BsIgG at up to 100 nM with cells that do not express either target antigen, and then detecting bound IgG with anti-human IgG Alexa Fluor 647 by flow cytometry. Only the BsIgG with the 10x polyhistidine tag showed evidence of non-specific binding (Fig. S13).

Based on these results, an ion exchange protocol was developed for the 8x polyhistidine-tag BsIgG that could be used for...
all BsIgG regardless of their variable domain isoelectric points. This enabled the development of a fully automated FPLC purification process that produces high purity BsIgG in the final formulation buffer from a 50 mL culture in 2.5 hours (Fig. 4A). This process was used to generate 285 BsIgGs toward 4-1BB with an average yield of 2.0 ± 1.1 mg. In situations where lower quantities of antibody are required and higher throughput is desired, the process throughput can be increased using high performance liquid chromatography (HPLC). Interestingly, these BsIgGs were already 79 ± 13% pure after Protein A purification.

**Antibody-induced 4-1BB signaling**

4-1BB is a co-stimulatory receptor expressed on the surface of activated immune cells, including T cells. Interaction with its ligand, 4-1BBL, activates the NFκB signaling cascade, resulting in increased T cell cytotoxicity and survival, and thus enhanced tumor clearance. We and others have shown that agonistic antibodies toward 4-1BB can be used to mimic this interaction, and agonistic anti-4-1BB antibodies have been shown to have a clinical benefit in multiple cancer indications. However, these antibodies are specific for human 4-1BB, which makes it challenging to dissect their mechanism of action using fully immunocompetent mouse models. To address this issue, the common light chain antibodies described above were generated toward mouse 4-1BB. These surrogate antibodies can be used as tools to increase our understanding of the underlying biology of this therapeutic approach and potentially improve upon it.

Common light chain antibodies with a range of affinities and epitopes toward mouse 4-1BB were expressed as either traditional IgGs or BsIgG, and then their ability to induce 4-1BB signaling was determined using an *in vitro* cell based assay (Fig. S14). Since agonistic antibodies toward 4-1BB and other receptors frequently depend upon Fc gamma receptor (FcγR) engagement to induce signaling, the antibodies were immobilized to mimic FcγR-mediated crosslinking, then incubated with HEK293T cells transduced with mouse 4-1BB and an NFκB luciferase reporter. The results from this type of cell line correlate well with those from stimulated primary T cells and allow direct comparison of antibodies across multiple assays by avoiding donor T cell variability. Both monoclonal and bispecific antibodies with a wide range of activity with regards to both EC₅₀ and maximum signaling intensity were identified (Fig. 5). Surprisingly, there was no apparent correlation between EC₅₀ and antibody affinity or epitope, and the most potent molecule was a monoclonal antibody (mAb117). None of the antibodies induced 4-1BB signaling when co-incubated in solution with the HEK293T reporter cell line (data not shown) as expected from similar experiments conducted with antibodies targeting human 4-1BB.

**Discussion**

We developed a synthetic human antibody library based on undiversified common light chains to generate antibodies with biophysical and biochemical properties indistinguishable from traditional monoclonal antibodies, which is critical for successful therapeutic development. We demonstrated how this library can be used to generate large panels of high affinity antibodies that bind diverse epitopes on a variety of antigens. In contrast to previous work, at least 10 antibodies with single-digit nanomolar affinities were isolated directly from the libraries toward each antigen and at least one antibody based on each of the three common light chains was identified. Further, the binding kinetics were determined at 37°C so the affinity...
of replicates to an
tive luminescence units (RLU) for each antibody was normalized to the positive control included on the same assay plate. High throughput screening limited the number
each of 6 concentrations (Fig. S13).

Figure 5. Antibody induced 4-1BB. Both monospecific and bispecific antibodies with a range of EC50 and maximum signaling levels were generated. The positive control is the commercially available anti-mouse 4-1BB antibody MAB9371 (red dashed) and the negative control is an antibody toward an irrelevant antigen (black dashed). The sample name includes the antibody affinity. All antibodies were generated with human IgG2aD D265A Fcs with or without the bispecific EEE or RRRR mutations. The rela-
tive luminescence units (RLU) for each antibody was normalized to the positive control included on the same assay plate. High throughput screening limited the number of replicates to an N of 1 or 2 for all antibodies with the exception of MAB9371 which had an average standard deviation of 0.06 normalized RLU over 10 replicates at
each of 6 concentrations (Fig. S13).

Figure 5. Antibody induced 4-1BB. Both monospecific and bispecific antibodies with a range of EC50 and maximum signaling levels were generated. The positive control is the commercially available anti-mouse 4-1BB antibody MAB9371 (red dashed) and the negative control is an antibody toward an irrelevant antigen (black dashed). The sample name includes the antibody affinity. All antibodies were generated with human IgG2aD D265A Fcs with or without the bispecific EEE or RRRR mutations. The rela-
tive luminescence units (RLU) for each antibody was normalized to the positive control included on the same assay plate. High throughput screening limited the number of replicates to an N of 1 or 2 for all antibodies with the exception of MAB9371 which had an average standard deviation of 0.06 normalized RLU over 10 replicates at
each of 6 concentrations (Fig. S13).

Figure 5. Antibody induced 4-1BB. Both monospecific and bispecific antibodies with a range of EC50 and maximum signaling levels were generated. The positive control is the commercially available anti-mouse 4-1BB antibody MAB9371 (red dashed) and the negative control is an antibody toward an irrelevant antigen (black dashed). The sample name includes the antibody affinity. All antibodies were generated with human IgG2aD D265A Fcs with or without the bispecific EEE or RRRR mutations. The rela-
tive luminescence units (RLU) for each antibody was normalized to the positive control included on the same assay plate. High throughput screening limited the number of replicates to an N of 1 or 2 for all antibodies with the exception of MAB9371 which had an average standard deviation of 0.06 normalized RLU over 10 replicates at
each of 6 concentrations (Fig. S13).

We have observed limited improvement compared to these previous reports is likely even higher since they used lower temperatures, which typically results in lower K_D values.57

Our common light chain antibodies have similar affinities and epitope coverage compared to antibodies with diversified light chains, and they can also be affinity matured in pools using a parallel library-based approach analogous to that employed for traditional antibodies.48

This approach resulted in antibodies with 10-fold higher average affinities compared to antibodies isolated directly from the library, which is similar to what others have accomplished when affinity maturing common light chain antibodies on an individual basis, but it drastically expedites the process since hundreds of antibodies are affinity matured in parallel.26

Further, these antibodies maintained their specificity and breadth of epitope coverage, which is critical for obtaining antibodies with the desired function. This was readily accomplished since the library contained germline-specific restrictions sites in the framework regions that were used to recombine the antigen-specific antibody CDR-H3 sequences obtained from the initial panning with up to nearly a billion CDR-H1 and CDR-H2 sequence combinations to find a more optimal pairing. The incorporation of this step further justifies minimizing CDR-H3 redundancy in the library design. In essence, this process mimics the natural antibody diversification process that occurs in B cells where the heavy and light chain pairing is established then the antibody is affinity matured through rounds of somatic hypermutation.

Generating sufficient quantities of BslgGs has been a major limitation to their discovery. Here, we demonstrated that single cell expression of common light chain BslgGs with complementary Fcs that facilitated preferential heterodimerization are 79% pure following protein A purification alone, which is dramatically higher than the 25% expected for BslgGs requiring two different light chains. In instances where the functional screen is tolerant of this level of purity, thousands of BslgGs could be generated using 96-well plate expression and purification approaches for initial screening. However, this level of purity is neither sufficient for all functional assays nor acceptable for accurate functional assessment and additional characterization. To address this issue, we developed a simple approach coupled with an automated continuous purification process based on existing bispecific antibody manufacturing techniques16 to enable the purification of highly pure common light chain BslgG at the milligram scale in 2.5 hours without the need for per-antibody customization. The key to developing this process was the incorporation of a small polyhistidine tag on the C-terminus of one of the heavy chains, which results in robust and reproducible separation of the contaminating monospecific antibodies from the desired BslgG during the IEC step. While our approach was based on accentuating the pI difference that exists between the two heavy chains that preferentially heterodimerize using our BslgG technology,16 it could be used with any Fc heterodimerization technology, such as the commonly used knobs-into-holes approach.59

It has become apparent that the therapeutic mechanisms of actions of many cancer immunotherapies are complex and will require the use of immuno-competent mouse models to more comprehensively understand the underlying biology.59,60 Many therapeutic antibodies, however, do not cross-react with their mouse counterparts due to low sequence homology. This includes antibodies toward 4-1BB, which has been shown to be a therapeutically important T cell costimulatory receptor.53,54

While the most advanced antibodies showed early evidence of clinical activity, they have different safety profiles, which could be the result of antibody intrinsic differences, such as their affinities, epitopes or Fc isotypes, or extrinsic differences, such as the patient populations treated.61 Surrogate antibodies that recognize mouse 4-1BB are required to investigate these ques-
tions in syngeneic mouse models. To help with this future work, we used the methods described above to generate tradi-
tional monoclonal antibodies toward mouse 4-1BB, as well as dozens of highly pure bispecific antibodies per week and hun-
dreds overall with minimal human involvement. This enabled us to find antibodies that induce mouse 4-1BB signaling with a range of activity. While more potent antibodies were identified compared to existing antibodies, none of the antibodies were able to induce FcyR-independent activation,9 including BslgGs derived from antibodies with non-overlapping epitopes. These
antibodies will serve as valuable tools to enable further dissection of antibody-mediated modulation of 4-1BB in immuno-competent mouse models in an attempt to find more optimal therapeutic antibodies.

Another important aspect of the common light chain antibodies generated here is the origin of their synthetic antibody sequences. Not only are the heavy chains sequences designed to look indistinguishable from antibodies derived from humans, but the common light chain sequences used are based on the germline sequences of light chains that are frequently used by humans and the exact sequence was found in nearly all individuals sequenced. They are thus potentially less immunogenic than traditional monoclonal antibodies that contain non-germline light chain sequences. Further, they have biophysical properties typical of therapeutic IgGs which makes them suitable for both therapeutic monoclonal and bispecific antibody development.

Overall, we developed a process to generate high affinity common light chain antibodies with broad epitope coverage by mimicking the natural antibody evolutionary process. BsIgG based on common light chain antibodies can be easily discovered and generated, resulting in antibodies with biochemical and biophysical properties that are indistinguishable from traditionally generated human antibodies. This approach allows more antibodies to be evaluated preclinically, and will hopefully lead to BsIgGs with more optimal therapeutic properties.

**Materials and methods**

**Antibody discovery**

Antigens containing a C-terminal 8x polyhistidine tag and AviTag (Avidity LLC) were expressed using the Expi293 system (Thermo Fisher Scientific), and then purified on an AKTA Avant (GE Healthcare) using a HisTrap excel (GE Healthcare) column followed by a Superdex 200 Increase GL (GE Healthcare) column according to the manufacturer’s protocols. Site-specific biotinylation through the AviTag (Avidity, Cat. No. BirA-500) was performed according to the manufacturer’s protocols. The VH libraries were synthesized using the Slonomics technology (MorphoSys) in a manner similar to that previously described. The phage displayed library was prepared and biopanning performed with site-specifically biotinylated antigen using an established protocol as a guideline. Automated phage ELISAs were based on previously described methods. For higher affinity antibody generation, the CDR-H3 sequences were recovered from phages from the 4th round of biopanning by PCR using VH FW3 and VL FW1 germline-specific primers, subcloned into a phagemid containing the cognate VL and CDR-H1 and CDR-H2 library; the phage-displayed library was then prepared, biopanning performed and antibody screening performed using phage ELISAs in a manner similar to what is described above. Full details are described in Supplemental materials.

**Antibody expression and purification**

The variable heavy chain domain from the antibody fragments were recovered by PCR and subcloned into a mammalian expression vector for full-length human IgG expression, then expressed using the Expi293 system. Purification was performed using an AKTA Avant (GE Healthcare) equipped for multistep tandem purification in a manner similar to that previously described. Traditional IgGs were purified from conditioned medium with a HiTrap column (GE Healthcare) column followed by a HiPrep Desalting Column (GE Healthcare) according to the manufacturer’s protocols. A 280-based watch conditions were implemented during the HiTrap MabSelect Sure purification elution phase to direct the eluate to the HiPrep Desalting Column. For bispecific IgG purification, the eluate from the HiTrap column was directed to the HiPrep Desalting Column followed by purification with MonoS GL (GE Healthcare) HiPrep and an additional HiPrep Desalting Column purification step. A 280-based watch conditions were implemented during the initial HiPrep Desalting Column purification to direct the eluate to the MonoS GL column. Unless otherwise indicated, the MonoS GL purification was performed with a multistep protocol consisting of a step gradient to 25% Buffer B for 5 column volumes, a linear gradient of 25–75% Buffer B over 40 column volumes and a step gradient to 100% Buffer B for 5 column volumes with a 280-based watch conditions implemented during the linear gradient phase to direct the eluate to the HiPrep Desalting Column. Full details are described in in Supplemental materials.

**Antibody characterization**

The molecular weights were determined using multi-angle light scattering and the thermal stability determined using differential scanning calorimetry as previously described. Antibody binding kinetics and affinities were determined by SPR using a Biacore 4000 biosensor (GE Lifesciences) similar to a manner previously described. Antibody epitope binning was performed using a previously described sandwiching technique with the exception of modifications for antibody capture and regeneration and a combination of SPR and BLI was used. An automated mouse 4-1bb signaling assay was based on a previously described method. Full details are described in in Supplemental materials.

**Abbreviations**

BLI | Bio layer interferometry
---|---
BsIgG | bispecific IgG
CDR | complementarity determining region
CDR-H | heavy chain CDR
CDR-L | light chain CDR
DSC | differential scanning calorimetry
EGFR | epidermal growth factor receptor
FcγR | Fc gamma receptor
FPLC | fast protein liquid chromatography
FW | framework
HMWS | higher molecular weight species
HPLC | high-performance liquid chromatography
IEX | ion exchange chromatography
pI | isoelectric point
ROR2 | receptor tyrosine kinase-like orphan receptor 2
scFv single-chain variable fragment
SEC-MALS size exclusion chromatography with multi-angle light scattering
ssDNA single-stranded DNA
SPR surface plasmon resonance
VH heavy chain variable domain
VL light chain variable domain
4-1BB tumor necrosis factor receptor superfamily member 9

Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.

Acknowledgments
We would like to thank Dr. Ralf Strohner and Dr. Stefan Arnold from Morphosys for training us on the Slonomics® technology. We are grateful to Dilduz Telman and Lora Zhao of Pfizer Inc. for their technical assistance with 454 pyrosequencing and Yik Andy Yeung of Pfizer Inc. for help developing the phage panning protocols. We are appreciative of Timothy Fisher of Pfizer Inc. for sharing the reporter cell line we used to functionally characterize some of the 4-1BB antibodies. We would also like to thank Hoang Tran from GE Healthcare for helping set-up the tandem purification using the Avant FPLC (GE). And finally, we would like to thank Barbara Sasu, Shahram Salek-Ardakani and Yik Andy Yeung of Pfizer Inc. for their careful review of the manuscript.

ORCID
Kevin Lindquist http://orcid.org/0000-0001-6059-7425
Steven Pitts http://orcid.org/0000-0002-9673-7394
Meri Galindo Casas http://orcid.org/0000-0002-5034-1722

References
1. Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leukemia & lymphoma. 2009;50:886–91. doi:10.1016/j.leuklym.2009.02.007.
2. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Molecular cancer therapeutics. 2012;11:582–93. doi:10.1158/1535-7163.MCT-11-0820.
3. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs. 2011;3:273–88. doi:10.4161/mabs.3.3.15188.
4. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhhu S, Watts RJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for its transcytosis target. Sci Transl Med. 2011;3:84ra44. doi:10.1126/scitranslmed.3002230.
5. Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenhauser K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monoclonal bispecific IgG design. mAbs. 2015;7:377–89. doi:10.1080/19420862.2015.1007816.
6. Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Archives of biochemistry and biophysics. 1961;93:460–2. doi:10.1016/0003-9861(61)90296-X.
7. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular immunology. 2015;67:95–106. doi:10.1016/j.molimm.2015.01.003.
8. Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulous M, Cook R, Slaga D, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRHS/CD3 and Is a Requirement for Myodma Cell Killing. Cancer cell. 2017;31:383–95. doi:10.1016/j.ccell.2017.02.001.
9. White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghani-Azadi K, Penfold CA, Booth SG, Doddy A, Polak ME, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticaner antibodies. Cancer cell. 2015;27:138–48. doi:10.1016/j.ccell.2014.11.001.
10. Jost C, Schilling J, Tamasvichov R, Schwill M, Honegger A, Pluckthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure. 2013;21:1979–91. doi:10.1016/j.str.2013.08.020.
11. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabianor H, Wehrman TS, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 2015;160:1196–208. doi:10.1016/j.cell.2015.02.011.
12. Kitazawa T, Iwaga T, Sanpei Z, Muto A, Kojima T, Sodera T, Yoshishashi K, Okuyama-Nishida Y, Saito H, Tsumoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature medicine. 2012;18:1570–4. doi:10.1038/nm.2942.
13. Brinkmann M, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9:182–212.
14. Labrijn AF, Meesters JI, de Goeij BJ, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:5145–50. doi:10.1073/pnas.1220451110.
15. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yanusara DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nature biotechnology. 2013;31:753–8. doi:10.1038/nbt.2621.
16. Shanop P, Ho WJ, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. Journal of molecular biology. 2012;420:204–19. doi:10.1016/j.jmb.2012.04.020.
17. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nature biotechnology. 2014;32:191–8. doi:10.1038/nbt.2797.
18. Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurenton A, Gueneau F, Ravn U, Depoisier JF, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nature communications. 2015;6:6113. doi:10.1038/ncomms7113.
19. Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nature protocols. 2014;9:2450–63. doi:10.1038/nprot.2014.169.
20. Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D, et al. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. mAbs. 2017;9:213–30.
21. Liu Z, Leng EC, Gusevskarean K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. The Journal of biological chemistry. 2015;290:7535–62. doi:10.1074/jbc.M114.620260.
22. Merchant AM, Zhu Z, Yuan Q, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nature biotechnology. 1998;16:677–81. doi:10.1038/370977.
23. Sharkey B, Pudi S, Wallace Moyer J, Zhong L, Prinz B, Baruh H, et al. Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. mAbs. 2017;9:257–68.
24. Ward ES. VH shuffling can be used to convert an Fv fragment of anti-egg hen lysosome specificity to one that recognizes a T cell receptor V alpha. Molecular immunology. 1995;32:147–56. doi:10.1016/0161-5890(94)00119-L.
25. Krah S, Schröt C, Eller C, Rhiel L, Rasche N, Beck J, et al. Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display. Protein Eng Des Sel. 2017;30:291–301. doi:10.1093/protein/gzw077.

26. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits LGR signaling. The Journal of biological chemistry. 2010;285:20850–9. doi:10.1074/jbc.M110.113910.

27. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. Antibody fragments from a single pot phage display library as immunological reagents. The EMBO journal. 1994;13:692–8.

28. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cytomolgus monkeys. Scientific reports. 2015;5:17943. doi:10.1038/srep17943.

29. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature biotechnology. 2005;23:1126–36. doi:10.1038/nbt1142.

30. Tillner T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biological properties. mAbs. 2013;5:445–70. doi:10.4161/mabs.24218.

31. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:20216–21. doi:10.1073/pnas.0909775106.

32. DeKosky BJ, Kojima T, Rodin A, Charab W, Ippolito GC, Ellington AD, et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nature medicine. 2015;21:86–91. doi:10.1038/nm.3743.

33. Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. Journal of molecular biology. 1987;199:901–17. doi:10.1016/0022-2836(87)90412-8.

34. Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. Journal of molecular biology. 2005;347:773–89. doi:10.1016/j.jmb.2005.01.053.

35. Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. Journal of molecular biology. 2003;325:531–53. doi:10.1016/s0022-2836(02)01237-8.

36. Raghunathan G, Smart J, Williams J, Almagro JC. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. Journal of molecular recognition: JMR. 2012;25:103–13. doi:10.1002/jmr.2158.

37. Zhai W, Glanville J, Fuhrmann M, Mei L, Ni I, Sundar PD, et al. Synthetic antibodies designed on natural sequence landscapes. Journal of molecular biology. 2011;412:55–71. doi:10.1016/j.jmb.2011.07.018.

38. Van den Brulle J, Fischer M, Langmann T, Horn G, Waldmann T, Arnold S, et al. A novel solid phase technology for high-throughput gene synthesis. BioTechniques. 2008;45:340–3. doi:10.2144/00012953.

39. Fath S, Bauer AP, Liss M, Spiersbach A, Maertens B, Hahn P, et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS one. 2011;6:e17596. doi:10.1371/journal.pone.0017596.

40. Maertens B, Spiersbach A, von Groll U, Roth U, Kubicek J, Gerrits M, et al. Gene optimization mechanisms: a multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli. Protein Sci. 2010;19:1312–26. doi:10.1002/pro.408.

41. Miersch S, Sidhu SS. Synthetic antibodies: concepts, potential and practical considerations. Methods. 2012;57:486–98. doi:10.1016/j.ymeth.2012.06.012.

42. Jain T, Sun T, Ozkan S, Hall A, Houston NR, Nett JH, et al. Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences of the United States of America. 2017;114:944–9. doi:10.1073/pnas.1616408114.

43. Lee CV, Sidhu SS, Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. Journal of immunological methods. 2004;284:119–32. doi:10.1016/j.jim.2003.11.001.

44. Fagerstam LG, Frostell A, Karlsson R, Kullman M, Larsson A, Malmqvist M, et al. Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping. Journal of molecular recognition: JMR. 1990;3:208–14. doi:10.1002/jmr.300030507.

45. Abdiche YN, Harriman R, Deng X, Yeung YA, Miles A, Morishige W, et al. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms. mAbs. 2016;8:264–77. doi:10.1080/19429862.2015.1118596.

46. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000;13:37–45. doi:10.1016/s1074-7613(00)00006-6.

47. Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26:663–70. doi:10.1093/protein/gzt047.

48. Prasler J, Steidl S, Uerlinger S. In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology. Immunotherapy. 2009;1:571–83.

49. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature. 1991;352:624–8. doi:10.1038/352624a0.

50. Kang AS, Jones TM, Burton DR. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proceedings of the National Academy of Sciences of the United States of America. 1991;88:11120–3. doi:10.1073/pnas.88.24.11120.

51. Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. Methods in enzymology. 2000;328:333–63. doi:10.1016/S0076-6879(00)28406-1.

52. Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB-4-1BB ligand in cancer immunotherapy. Cancer gene therapy. 2004;11:215–26. doi:10.1038/sj.cgt.7000670.

53. Fisher TS, Kampserschroer C, Oliphant T, Love VA, Lira PD, Doynnas R, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances the T-cell function and promotes anti-tumor activity. Cancer immunology, immunotherapy: CII. 2012;61:1721–33. doi:10.1007/s00262-012-1237-1.

54. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature medicine. 1997;3:682–5. doi:10.1038/nm0697-682.

55. Tolcher AW, Szoln M, Hu-Lieskovs K, Papadopoulos K, Patnaik A, Rasco DW, et al. Phase Ib Study of Uytomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical cancer research: an of clinical journal of the American Association for Cancer Research. 2017;23:5349–57. doi:10.1158/1078-0432.CCR-17-1243.

56. Wakefield I, Stephens S, Foukles R, Neshitt A, Bourne T. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab monoclonal antibody. Toxicological sciences. 2005;90:55–65. doi:10.1093/toxsci/kfi030.

57. Chung MC, Marroqui M, Kirn D, Bedi AS, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:E2646–54. doi:10.1073/pnas.1604268113.
61. Perez-Ruiz E, Etxeberria I, Rodriguez-Ruiz ME, Melero I. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017;23:5326–8. doi:10.1158/1078-0432.CCR-17-1799.

62. Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. Journal of molecular biology. 2004;338:299–310. doi:10.1016/j.jmb.2004.02.050.

63. Yoo D, Provchy J, Park C, Schulz C, Walker K. Automated high-throughput protein purification using an AKTApurifier and a CETAC autosampler. Journal of chromatography A. 2014;1344:23–30. doi:10.1016/j.chroma.2014.04.014.

64. Safsten P, Klakamp SL, Drake AW, Karlsson R, Myszka DG. Screening antibody-antigen interactions in parallel using Biacore A100. Anal Biochem. 2006;353:181–90. doi:10.1016/j.ab.2006.01.041.